Skip to content

Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol

Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 1. Evaluating the Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol (DOPET).

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01788670
Enrollment
24
Registered
2013-02-11
Start date
2009-05-31
Completion date
2010-06-30
Last updated
2013-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contribution of Ethanol on Hydroxytyrosol Formation

Keywords

Antioxidants, Central Nervous System Agents

Brief summary

Health benefits for humans derived from low dose intake of ethanol could partially be explained by its interaction with dopamine (DA) oxidative metabolism. Ethanol is expected to induce an increase in the formation of a DA minor metabolite: DOPET (hydroxytyrosol). Hydroxytyrosol is one of the most potent antioxidants present in Mediterranean Diet. The study is aimed at establishing the contribution of ethanol on hydroxytyrosol formation.

Interventions

DIETARY_SUPPLEMENTEthanol
OTHERWater

Sponsors

Fundacion IMIM
CollaboratorOTHER
Parc de Salut Mar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical history and physical examination demonstrating no organic or psychiatric disorders. * The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically. * The body mass index (BMI=weigh/height2) will range from 19 to 27 kg/m2, and the weight from 50 to 110 kg. * Understanding and accepting the study procedures and signing the informed consent.

Exclusion criteria

* Not meeting the inclusion criteria. * History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs. * Having suffered any organic disease or major surgery in the three months prior to the study start. * History of psychiatric disorders. * Smokers of more than 20 cigarettes per day. * Taking more than 30 g of alcohol a day * Regular use of any drug in the month prior to the study sessions.The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session. * Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks. * Subjects with intolerance or adverse reactions to ethanol * History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs. * Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed. * Subjects with positive serology to Hepatitis B, C or HIV. To be eligible, the subjects must agree to follow a diet free from ethanol and olive oil in the 72 hours prior to the start of each session and until the end of the study.

Design outcomes

Primary

MeasureTime frameDescription
Hydroxytyrosol biological fluids concentrations0-24h after administrationHydroxytyrosol concentrations in plasma and urine

Secondary

MeasureTime frameDescription
Subjective drunkenness0-6h after administrationEthanol subjective effects measured using a visual analog scale
Vital signs0-6h after administrationBlood pressure, oral temperature and heart rate
Ethanol concentration0-6h after administrationEthanol blood concentrations
Ethanol metabolites concentrations0-24h after administrationEthanol metabolites recovery in urine
Dopamine metabolites concentrations0-24h after administrationDopamine metabolites recovery in urine

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026